Intas to provide 2 million hydroxychloroquine tablets for WHO study on COVID-19

Ahmedabad: Intas Pharmaceuticals Ltd. has said it will provide up to two million tablets of hydroxychloroquine to World Health Organisation-endorsed study into the prevention of COVID-19 infection using hydroxychloroquine, free of charge, along with two million tablets of matched placebo.

Intas informed that it is collaborating on the WHO-endorsed study using hydroxychloroquine, a drug that may have an effect in preventing and/or reducing symptoms of COVID-19. The global COPCOV (chloroquine / hydroxychloroquine prevention of COVID-19 in the healthcare setting; a randomised, placebo-controlled prophylaxis) study involves 40,000 frontline healthcare workers who are caring for COVID-19 patients and is due to start shortly.

Binish Chudgar, VC at Intas Pharmaceuticals Ltd. said in addition to providing scientific advice, the company’s teams are working overtime to manufacture the required hydroxychloroquine and matching-placebo for this vital study.